论文部分内容阅读
对20例经手术切除的进展期肿瘤患者用活化的自身肿瘤浸润淋巴细胞（TIL）和重组人白细胞介素－2（rhIL－2）治疗，并检测治疗前后细胞免疫变化。患者的PBL对同种异体相同组织学类型靶细胞的细胞毒性明显升高（P＜0．05），而对无关靶细胞的细胞毒性无明显变化（P＞0．05）；外周血淋巴细胞产生IL－2的能力均有明显的提高，从12．3U／ml到19．8U／ml（P＜0．01）；对植物血凝素（PHA）皮试反应性明显增强，反应直径从8．6mm升高到13．5mm（P＜0．01）。TIL输注过程中，11例有一过性寒战、发热（T＜38℃），其中6例伴轻度恶心、呕吐。结果提示：单次输注TIL和小剂量rhIL－2综合治疗后，可明显提高进展期肿瘤患者的细胞免疫功能，而无严重毒副作用，可能成为进展期肿瘤术后重要的辅助治疗方法。
Twenty cases of advanced resected advanced cancer patients were treated with activated TIL and rhIL-2, and the changes of cellular immunity before and after treatment were detected. The cytotoxicity of PBL in target cells of the same histological type was significantly increased (P <0.05), while the cytotoxicity of unrelated target cells was not significantly changed (P> 0.05). The peripheral blood lymphocytes (P <0.01). The reactivity to PHA skin test was obviously enhanced, and the reaction diameter increased from 12.3U / ml to 19.8U / ml 8.6 mm up to 13.5 mm (P <0.01). During TIL infusion, 11 patients had transient chills and fever (T <38 ° C), of which 6 had mild nausea and vomiting. The results suggest that the single infusion of TIL and low-dose rhIL-2 combined treatment can significantly improve the cellular immune function in advanced cancer patients without serious side effects, which may be an important adjuvant therapy for advanced cancer after surgery.